Table 1 Characteristics of the included studies
Study [Ref.] | Year | Country (City) | Study design | Genotyping | Numbers | Gender (M/F) | Age | Polymorphism (s) | Quality score | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OA | Control | OA | Control | OA | Control | Â | Â | |||||
Toshio Ushiyama et al. [24] | 1998 | Japan | Case–control | PCR | 65 | 318 | 0/65 | 0/318 | 68.5 (49–86) | 49-86 | XbaI, PvuII | 7 (2/2/3) |
John Loughlin et al. [29] | 2000 | UK (Oxford) | Case–control | PCR | 371 | 369 | 155/216 | 221/148 | 73 (56–90) | 73 (59–89) | XbaI, PvuII | 8 (3/2/3) |
Barton L. Wise et al. [30] | 2009 | USA | Cohort | PCR | 307 | 214 | 258/263 | 61 ± 9 | XbaI | 8 (4/2/2) | ||
Barton L. Wise et al. [30] | 2009 | USA | Cohort | PCR | 304 | 211 | 253/262 | 61 ± 9 | PvuII | |||
V. M. Borgonio-Cuadra et al. [32] | 2012 | Mexico | Case–control | PCR | 115 | 117 | 23/92 | 20/97 | 57.4 ± 9.2 | 51.8 ± 8.9 | XbaI, PvuII | 9 (4/2/3) |
J. A. Riancho et al. [33] | 2010 | Spain (Santander) | Case–control | PCR | 272 | 802 | 95/177 | 285/517 | 72 ± 7 | 71 ± 10 | PvuII | 8 (3/2/3) |
J. A. Riancho et al. [33] | 2010 | Spain (Santiago) | Case–control | PCR | 254 | 473 | 47/207 | 295/178 | 68 ± 6 | 68 ± 9 | PvuII | |
J. A. Riancho et al. [33] | 2010 | UK (Oxford) | Case–control | PCR | 445 | 862 | 176/269 | 471/391 | 64 ± 5 | 69 ± 7 | PvuII | |
J. A. Riancho et al. [33] | 2010 | Spain (Santander) | Case–control | PCR | 359 | 802 | 180/179 | 285/517 | 71 ± 7 | 71 ± 10 | PvuII | |
J. A. Riancho et al. [33] | 2010 | Spain (Coruña) | Case–control | PCR | 252 | 244 | 90/162 | 97/147 | 67 ± 14 | 65 ± 13 | PvuII | |
J. A. Riancho et al. [33] | 2010 | Spain (Santiago) | Case–control | PCR | 287 | 473 | 110/177 | 295/178 | 68 ± 5 | 68 ± 9 | PvuII | |
J. A. Riancho et al. [33] | 2010 | UK (Oxford) | Case–control | PCR | 1278 | 862 | 503/775 | 471/391 | 65 ± 6 | 69 ± 7 | PvuII | |
K. Lian M.D. et al. [31] | 2007 | USA | Cohort | PCR | 569 | 4134 | 0/569 | 0/4134 | 79.6 ± 5.0 | 78.4 ± 4.6 | XbaI, PvuII | 8 (4/2/2) |
Sheng-Yu Jin et al. [25] | 2004 | Korea | Case–control | PCR | 151 | 397 | 53/98 | 190/207 | 58.8 ± 9.6 | / | XbaI, PvuII | 8 (3/2/3) |
Zhi Tian et al. [28] | 2009 | China | Case–control | PCR | 38 | 40 | 0/38 | 0/40 | 59.2 ± 3.2 | 58.5 ± 8.6 | XbaI, PvuII | 7 (2/2/3) |
Jiexiang Yang et al. [34] | 2009 | China | Case–control | PCR | 41 | 40 | 31/50 | 54.6 (28–82) | XbaI, PvuII | 6 (2/1/3) | ||
Yan Xue et al. [27] | 2004 | China | Case–control | PCR | 55 | 176 | 0/55 | 0/176 | 58.7 ± 2.4 | 60 ± 10 | XbaI, PvuII | 7 (3/1/3) |
Xiaoyu Dai et al. [26] | 2014 | China | Case–control | PCR | 469 | 522 | 113/356 | 398/124 | 57.3 ± 10.9 | 56.4 ± 9.8 | XbaI, PvuII | 7 (3/1/3) |